We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





POC COVID-19 Test Detects and Differentiates SARS-CoV-2 Alpha Variant from Earlier Strains

By LabMedica International staff writers
Posted on 20 Apr 2022

A newly-developed point-of-care COVID-19 test can detect and differentiate the alpha variant of the SARS-CoV-2 virus from earlier strains in saliva samples. More...

The new test developed by researchers at the University of Illinois at Urbana-Champaign (Champaign, IL, USA) builds on their previous developments, which allowed samples to bypass the laboratory – first using nasopharyngeal swabs, then with saliva samples. The point-of-care amplification and testing process, called LAMP, is more efficient than PCR because it does not require expensive thermal cycling machines. According to the researchers, the assay does not need RNA extraction and purification steps, similar to the Illinois saliva test.

The updated process takes advantage of a genetic phenomenon called S-gene target failure – which is present in the alpha variant but not in the SARS-CoV-2 virus early strains – to differentiate between the two alpha variants, the researchers said. During the new testing process, specially selected genetic primers are placed onto additively manufactured cartridges and dried before adding the patient samples. The chosen primers are set against the S-gene and are specific for detecting the S-gene target failure against 69–70 deletion in the alpha variant.

Their study confirmed the device’s effectiveness by testing 38 clinical saliva samples, including 20 samples positive for alpha variant. The researchers would like to refine their method to test up to five different viruses, viral strains and variants in a single test, compatible with nasal swab and saliva mediums.

“Our study shows that it is possible to test for variants of the same coronavirus strain in a single point-of-care test that takes 30 minutes using a portable handheld device,” said Rashid Bashir, a professor of bioengineering and the dean of the Grainger College of Engineering at Illinois, who co-led the study. “The new test is scalable to suit future pandemics, COVID-19 or otherwise, and could be used at home or other settings.”

“The new omicron variant also exhibits S-gene target failure and could be tested for by adapting the approach developed in this study,” added bioengineering professor Enrique Valera.

Related Links:
University of Illinois at Urbana-Champaign 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.